Tu1080: HELICOBACTER PYLORI (H. PYLORI) ANTIMICROBIAL RESISTANCE AND ERADICATION RATES IN AFRICA: A SYSTEMATIC REVIEW

WEO Newsletter

“…In developing countries like Nigeria, it has been shown that some antibiotic resistance rates can reach up to 100%, a significant reason for eradication failure. [10][11][12] Despite the alarming H. pylori antibiotic resistance and suboptimal eradication rates, there is a paucity of epidemiological and all-encompassing studies on the status of those rates.…”

“…During the ACG international training, Dr Chukwudike co-authored an article titled "Management of Helicobacter pylori in Africa: The challenges and peculiarities." 10 As part of the mentorship leading up to and during the clinical observership, Dr Chukwudike presented two abstracts, titled 'Helicobacter pylori eradication rates and antibiotic resistance patterns in Nigeria, West Africa: A systematic review 11 at the ACG 2021 Annual Scientific Meeting, and "Helicobacter pylori antimicrobial resistance and eradication rates in Africa: A systematic review" 12 at the 2022 Digestive Disease Week (DDW).…”

Clinical Implication of Drug Resistance for H. pylori Management

“…There have been several recent reviews and meta-analyses assessing H. pylori resistance rates to the antimicrobials that are commonly used in eradication regimens [ 3 , 4 , 5 ]. Although the availability and quality of such data is highly variable and is scant or non-existent for some regions, the general trend has been a steady rise in reported resistance to clarithromycin, levofloxacin and metronidazole over the last four decades since H. pylori resistance was first recognized.…”

“…Consequently, these three antimicrobials are increasingly being recommended in regimens in countries where resistance rates are high (>15%) and eradication rates suboptimal. We note that high rates of resistance to amoxicillin and tetracycline have been reported from some countries in Africa, but these reports are inconsistent across the continent for unclear reasons and may be due to methodological issues [ 5 ].…”

“…However, there were insufficient data to adequately illustrate rifabutin resistance. Areas in gray indicate no data available from the references that were used [ 3 , 4 , 5 ].…”